Clinical testing with inhibitors of other epigenetic regulators that are either mutated or recognized as non-oncogene dependencies in AML are also ongoing, including PRMT5, LSD1 and BRD4 inhibitors, although their roles in AML LSC-regulation is unclear (90). Here, BRD4 is linked to acute myeloid leukemia.